D-1054-2019 Class II Ongoing
FDA drug recall D-1054-2019 was initiated by Rising Pharmaceuticals, Inc. on Mar 7, 2019 and is designated Class II. Reason for recall: CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products The recall status is ongoing. Affected quantity: 35,281 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2019
- Initiation Date
- Mar 7, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 35,281 bottles
Product description
Valsartan Tablets 160 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810 ---- NDC 52343-124-90
Reason for recall
CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products
Distribution pattern
Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.
Code information
472180005B, exp. date 02/29/2020 472180011A, exp. date 04/30/2020 472180012A, exp. date 04/30/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1054-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026